CN111757941A - 多聚体抗dr5结合分子与化学治疗剂联合用于治疗癌症的用途 - Google Patents

多聚体抗dr5结合分子与化学治疗剂联合用于治疗癌症的用途 Download PDF

Info

Publication number
CN111757941A
CN111757941A CN201980014868.8A CN201980014868A CN111757941A CN 111757941 A CN111757941 A CN 111757941A CN 201980014868 A CN201980014868 A CN 201980014868A CN 111757941 A CN111757941 A CN 111757941A
Authority
CN
China
Prior art keywords
seq
ser
gly
thr
val
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201980014868.8A
Other languages
English (en)
Chinese (zh)
Inventor
B·T-Y·王
B·A·基特
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
IGM Biosciences Inc
Original Assignee
IGM Biosciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by IGM Biosciences Inc filed Critical IGM Biosciences Inc
Publication of CN111757941A publication Critical patent/CN111757941A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/63—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide
    • A61K31/635—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide having a heterocyclic ring, e.g. sulfadiazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5011—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing antineoplastic activity
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2510/00—Detection of programmed cell death, i.e. apoptosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Urology & Nephrology (AREA)
  • Microbiology (AREA)
  • Hematology (AREA)
  • Toxicology (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Mycology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CN201980014868.8A 2018-02-26 2019-02-25 多聚体抗dr5结合分子与化学治疗剂联合用于治疗癌症的用途 Pending CN111757941A (zh)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201862635033P 2018-02-26 2018-02-26
US62/635,033 2018-02-26
US201862767900P 2018-11-15 2018-11-15
US62/767,900 2018-11-15
PCT/US2019/019340 WO2019165340A1 (en) 2018-02-26 2019-02-25 Use of a multimeric anti-dr5 binding molecule in combination with a chemotherapeutic agent for treating cancer

Publications (1)

Publication Number Publication Date
CN111757941A true CN111757941A (zh) 2020-10-09

Family

ID=67688449

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201980014868.8A Pending CN111757941A (zh) 2018-02-26 2019-02-25 多聚体抗dr5结合分子与化学治疗剂联合用于治疗癌症的用途

Country Status (8)

Country Link
US (1) US20200392239A1 (https=)
EP (1) EP3759229A4 (https=)
JP (2) JP7358365B2 (https=)
KR (1) KR20200123782A (https=)
CN (1) CN111757941A (https=)
AU (1) AU2019224136A1 (https=)
CA (1) CA3091140A1 (https=)
WO (1) WO2019165340A1 (https=)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3105250B1 (en) 2014-02-10 2020-08-05 IGM Biosciences, Inc. Iga multi-specific binding molecules
PL3560954T3 (pl) 2014-04-03 2021-12-13 Igm Biosciences, Inc. Zmodyfikowany łańcuch J
IL308212A (en) 2015-01-20 2024-01-01 Igm Biosciences Inc Tumor necrosis factor-α receptor binding molecules and their uses
EP3957738A1 (en) 2015-03-04 2022-02-23 IGM Biosciences, Inc. Cd20 binding molecules and uses thereof
WO2016154593A1 (en) 2015-03-25 2016-09-29 Igm Biosciences, Inc. Multi-valent hepatitis b virus antigen binding molecules and uses thereof
CN107847591B (zh) 2015-04-17 2023-07-28 Igm生物科学股份有限公司 多价人免疫缺陷病毒抗原结合分子及其应用
EP3356401B1 (en) 2015-09-30 2020-06-24 IGM Biosciences, Inc. Binding molecules with modified j-chain
EP3355913B1 (en) 2015-09-30 2024-10-30 IGM Biosciences, Inc. Binding molecules with modified j-chain
SG11201809336QA (en) 2016-05-09 2018-11-29 Igm Biosciences Inc Anti-pd-l1 antibodies
MX2019011986A (es) 2017-04-07 2019-11-07 Igm Biosciences Inc Regiones constantes de igm humana modificadas para la modulacion de la funcion efectora de la citolisis dependiente de complemento referencia cruzada a solicitudes relacionadas.
MX2020009069A (es) 2018-03-01 2020-10-08 Igm Biosciences Inc Mutaciones de fc de igm y de la cadena j que afectan la semivida de igm en suero.
JP2022544405A (ja) 2019-08-15 2022-10-18 アイジーエム バイオサイエンシズ インコーポレイテッド 免疫刺激性多量体型結合分子
EP4139362A2 (en) 2020-04-22 2023-03-01 IGM Biosciences Inc. Pd-1 agonist multimeric binding molecules
JP2023526224A (ja) * 2020-05-12 2023-06-21 アイジーエム バイオサイエンシズ インコーポレイテッド がんを治療するための、がん治療薬との組合せでの多量体抗ｄｒ５結合分子の使用
EP4277706A1 (en) * 2021-01-15 2023-11-22 Stichting Het Nederlands Kanker Instituut- Antoni van Leeuwenhoek Ziekenhuis Inducers of senescence, in combination with a selective death receptor 5 (dr5) agonist, for use in a method of treating cancer
US12600801B2 (en) 2022-07-11 2026-04-14 Fred Hutchinson Cancer Center Single-domain antibodies that bind ROR1

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008066854A2 (en) * 2006-11-28 2008-06-05 Novartis Ag Methods and compositions for inducing apoptosis in cancer cells
US20080248046A1 (en) * 1997-03-17 2008-10-09 Human Genome Sciences, Inc. Death domain containing receptor 5
US20100080806A1 (en) * 2004-08-19 2010-04-01 Yanxin Liu Anti-human trail receptor dr5 monoclonal antibody (ad5-10), method thereof and use of the same
US20170320955A1 (en) * 2015-01-20 2017-11-09 Igm Biosciences, Inc. Tumor necrosis factor (tnf) superfamily receptor binding molecules and uses thereof

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PE20071101A1 (es) 2005-08-31 2007-12-21 Amgen Inc Polipeptidos y anticuerpos
CA2695991A1 (en) 2007-08-09 2009-02-12 Daiichi Sankyo Company, Limited Immunoliposome inducing apoptosis into cell expressing death domain-containing receptor
PH12013500845A1 (en) 2010-10-29 2013-06-24 Daiichi Sankyo Co Ltd Novel anti-dr5 antibody
EP2760891B1 (en) 2011-09-26 2018-11-07 JN Biosciences LLC Hybrid constant regions
EP2684896A1 (en) 2012-07-09 2014-01-15 International-Drug-Development-Biotech Anti-DR5 family antibodies, bispecific or multivalent anti-DR5 family antibodies and methods of use thereof
WO2014159562A1 (en) * 2013-03-14 2014-10-02 Bristol-Myers Squibb Company Combination of dr5 agonist and anti-pd-1 antagonist and methods of use
EP3356401B1 (en) 2015-09-30 2020-06-24 IGM Biosciences, Inc. Binding molecules with modified j-chain

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20080248046A1 (en) * 1997-03-17 2008-10-09 Human Genome Sciences, Inc. Death domain containing receptor 5
US20100080806A1 (en) * 2004-08-19 2010-04-01 Yanxin Liu Anti-human trail receptor dr5 monoclonal antibody (ad5-10), method thereof and use of the same
WO2008066854A2 (en) * 2006-11-28 2008-06-05 Novartis Ag Methods and compositions for inducing apoptosis in cancer cells
US20170320955A1 (en) * 2015-01-20 2017-11-09 Igm Biosciences, Inc. Tumor necrosis factor (tnf) superfamily receptor binding molecules and uses thereof

Also Published As

Publication number Publication date
JP2021514945A (ja) 2021-06-17
US20200392239A1 (en) 2020-12-17
WO2019165340A1 (en) 2019-08-29
CA3091140A1 (en) 2019-08-29
AU2019224136A1 (en) 2020-09-10
EP3759229A4 (en) 2021-12-29
JP2023159403A (ja) 2023-10-31
EP3759229A1 (en) 2021-01-06
KR20200123782A (ko) 2020-10-30
JP7358365B2 (ja) 2023-10-10

Similar Documents

Publication Publication Date Title
JP7358365B2 (ja) がんを治療するための、化学療法剤と併用した多量体抗ｄｒ５結合分子の使用
US20230203173A1 (en) Tumor necrosis factor (tnf) superfamily receptor igm antibodies and uses thereof
US20230174660A1 (en) Use of a multimeric anti-dr5 binding molecule in combination with a cancer therapy for treating cancer
BR112017018941B1 (pt) Molécula de ligação a cd20, seu uso, composição e método in vitro para direcionar a morte mediada por complemento de uma célula que expressa cd20
CN115956085A (zh) 转化生长因子β(TGFβ)结合剂及其用途
JP2025506341A (ja) 抗ｃｄ３８結合分子及びその使用
HK40043005A (en) Tumor necrosis factor (tnf) superfamily receptor binding molecules and uses thereof
CA2972990C (en) Tumor necrosis factor (tnf) superfamily receptor binding molecules and uses thereof
CN121152808A (zh) 抗ccr8抗体和抗ccr8/ctla4双特异性抗体
HK1242348A1 (en) Tumor necrosis factor (tnf) superfamily receptor binding molecules and uses thereof
HK1242348B (en) Tumor necrosis factor (tnf) superfamily receptor binding molecules and uses thereof

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
WD01 Invention patent application deemed withdrawn after publication
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20201009